Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Osteoporosis, Postmenopausal, Date of authorisation: 04/01/2007, Revision: 25, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 4, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Ovitrelle, choriogonadotropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female, Date of authorisation: 02/02/2001, Revision: 22, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 23, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Graft Rejection, Date of authorisation: 14/02/1996, Revision: 38, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/06/2015, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Human medicines European public assessment report (EPAR): Roteas, edoxaban, Stroke;Venous Thromboembolism, Date of authorisation: 19/04/2017, Revision: 11, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-10-04
Biological Products - Specific Labeling Resources
Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
GDUFA Type II API DMF Payment Receipts Report
Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
GDUFA Paid Facilities List
Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
PDUFA and BsUFA Quarterly Hiring Updates
Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
Coronavirus (COVID-19) | CBER-Regulated Biologics
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-10-03 By FDA
FDA Roundup: October 3, 2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-10-03 By FDA
FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-10-03 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.